logo
welcome
CNBC

CNBC

Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial

CNBC
Summary
Nutrition label

87% Informative

Eli Lilly's weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo.

Tirzepatide is the active ingredient in the company's popular weight loss injection Zepbound and diabetes drug Mounjaro .

Adults on the highest weekly dose of the drug saw a 22.9% decrease in body weight on average after 176 weeks .